What's Happening?
At ESMO 2025, Jane Li from Thermo Fisher Scientific discussed the importance of partnerships between pharmaceutical companies and diagnostic developers in advancing precision oncology. The recent FDA approval
of the oncomine Dx Target Test as a companion diagnostic for HERNEXEOS highlights the role of co-developing diagnostics with targeted therapies. These collaborations ensure accurate patient-drug matching, faster approvals, and greater access to breakthrough treatments.
Why It's Important?
Partnerships between pharma and diagnostic developers are essential for the advancement of precision oncology. By aligning early with regulators and co-developing companion diagnostics, these collaborations can accelerate the development and approval of targeted therapies. This approach enhances patient outcomes by ensuring that treatments are tailored to individual genetic profiles, improving efficacy and reducing side effects. The success of such partnerships could lead to more personalized and effective cancer treatments.
